# US 2022/0089742 A1 · Combined pharmaceutical composition for treating tumor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0089742 A1
- Document ID: US20220089742A1
- Status: Published application
- Kind: A1
- Application number: 17/425,006
- Filed: 2020-01-23
- Published: 2022-03-24
- Earliest claimed: 2019-01-25
- Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Nanjing Shunxin Pharmaceuticals Co., LTD. of Chiatai Tianqing Pharmaceutical Group
- Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group
- Inventors: Xiquan ZHANG; Xunqiang WANG; Chaoqiang YANG; Yuchen FAN; Mengxue FAN; Fan FENG; Nan SU; Yao LIU; Chi ZHANG; Hai JIANG
- Web page: https://patentgrep.com/patent/US20220089742A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 35/00: Antineoplastic agents
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to the field of biomedicine, and relates to a combined pharmaceutical composition for treating biliary tract tumor, liver cancer, triple negative breast cancer or lung cancer. The combined pharmaceutical composition comprises an anti-PD-L1 antibody and anlotinib, and has good anti-biliary tract tumor, liver cancer, triple negative breast cancer or lung cancer activity.

## Claims

### Claim 1

A combined pharmaceutical composition comprising an anti-PD-L1 antibody and anlotinib, wherein the anti-PD-L1 antibody comprises an amino acid sequence as follows: a heavy chain CDR1 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 4; a heavy chain CDR2 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 5; a heavy chain CDR3 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 6; a light chain CDR1 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 10; a light chain CDR2 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 8 or SEQ ID NO: 11; and a light chain CDR3 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 9 or SEQ ID NO: 12.

### Claim 2 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the combined pharmaceutical composition is used for treating a tumor in biliary system, liver cancer, triple negative breast cancer or lung cancer.

### Claim 3 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the combined pharmaceutical composition comprises a pharmaceutical composition of the anti-PD-L1 antibody and a pharmaceutical composition of anlotinib.

### Claim 4 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the combined pharmaceutical composition is packaged in a kit further comprising an instruction for combined use of the anti-PD-L1 antibody and anlotinib in treating a tumor in biliary system, liver cancer, triple negative breast cancer and/or lung cancer.

### Claim 5 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the combined pharmaceutical composition comprises a pharmaceutical composition containing 600-2400 mg of the anti-PD-L1 antibody and a pharmaceutical composition containing anlotinib in a single dose of 6 mg, 8 mg, 10 mg and/or 12 mg.

### Claim 6 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the combined pharmaceutical composition comprises the anti-PD-L1 antibody and the anlotinib in a weight ratio of (0.35-29):1, preferably (3.5-29):1.

### Claim 7 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the combined pharmaceutical composition is a formulation suitable for administration within a single treatment cycle, comprising a pharmaceutical composition containing 600-2400 mg of the anti-PD-L1 antibody and a pharmaceutical composition containing 84-168 mg of anlotinib.

### Claim at position 8

8-20. (canceled)

### Claim 21 (depends on 1)

A method for treating a tumor in biliary system, liver cancer, triple negative breast cancer and/or lung cancer, comprising administering to a subject an effective amount of the combined pharmaceutical composition according to claim 1.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the anti-PD-L1 antibody and anlotinib in the combined pharmaceutical composition are packaged either separately or together.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the anti-PD-L1 antibody and anlotinib are each in the form of a pharmaceutical composition that can be administered simultaneously, sequentially or at intervals.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the anti-PD-L1 antibody is administered once every week, every 2 weeks, every 3 weeks, or every 4 weeks at a dose of 600-2400 mg.

### Claim 25 (depends on 22)

The method according to claim 22, wherein anlotinib is administered at a dose of 6 mg, 8 mg, 10 mg, or 12 mg once daily with a regimen of 2-week treatment and 1-week interruption.

### Claim 26

A kit for use in treating a tumor in biliary system, liver cancer, triple negative breast cancer and/or lung cancer, comprising a pharmaceutical composition of an anti-PD-L1 antibody, a pharmaceutical composition of anlotinib, and an instruction for combined use of the anti-PD-L1 antibody and anlotinib in treating a tumor in biliary system, liver cancer, triple negative breast cancer and/or lung cancer, wherein the anti-PD-L1 antibody comprises an amino acid sequence as follows: a heavy chain CDR1 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 4; a heavy chain CDR2 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 5; a heavy chain CDR3 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 6; a light chain CDR1 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 10; a light chain CDR2 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 8 or SEQ ID NO: 11; and a light chain CDR3 region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 9 or SEQ ID NO: 12.

### Claim 27 (depends on 26)

The kit according to claim 26, wherein the kit is suitable for administration within a single treatment cycle, comprising a pharmaceutical composition containing 600-2400 mg of the anti-PD-L1 antibody and a pharmaceutical composition containing 84-168 mg of anlotinib.

### Claim 28 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the anti-PD-L1 antibody comprises an amino acid sequence as follows: a heavy chain CDR1 region selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 4; a heavy chain CDR2 region selected from the group consisting of SEQ ID NO: 2 and SEQ ID NO: 5; a heavy chain CDR3 region selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 6; a light chain CDR1 region selected from the group consisting of SEQ ID NO: 7 and SEQ ID NO: 10; a light chain CDR2 region selected from the group consisting of SEQ ID NO: 8 and SEQ ID NO: 11; and a light chain CDR3 region selected from the group consisting of SEQ ID NO: 9 and SEQ ID NO: 12.

### Claim 29 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the anti-PD-L1 antibody comprises: a heavy chain CDR1 region having an amino acid sequence set forth in SEQ ID NO: 1; a heavy chain CDR2 region having an amino acid sequence set forth in SEQ ID NO: 2; a heavy chain CDR3 region having an amino acid sequence set forth in SEQ ID NO: 3; a light chain CDR1 region having an amino acid sequence set forth in SEQ ID NO: 7; a light chain CDR2 region having an amino acid sequence set forth in SEQ ID NO: 8; and a light chain CDR3 region having an amino acid sequence set forth in SEQ ID NO: 9.

### Claim 30 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the anti-PD-L1 antibody comprises an amino acid sequence as follows: a heavy chain variable region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 13 or SEQ ID NO: 14; and a light chain variable region having at least 80% homology to an amino acid sequence set forth in SEQ ID NO: 15 or SEQ ID NO: 16.

### Claim 31 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the anti-PD-L1 antibody comprises: a heavy chain amino acid sequence set forth in SEQ ID NO: 17; and a light chain amino acid sequence set forth in SEQ ID NO: 18.

### Claim 32 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein the anti-PD-L1 antibody comprises: a heavy chain variable region selected from the group consisting of heavy chain variable regions of hu13C5-hIgG1, hu13C5-hIgG4, hu5G11-hIgG1 and hu5G11-hIgG4 humanized antibodies; and a light chain variable region selected from the group consisting of light chain variable regions of hu13C5-hIgG1, hu13C5-hIgG4, hu5G11-hIgG1 and hu5G11-hIgG4 humanized antibodies.

### Claim 33 (depends on 1)

The combined pharmaceutical composition according to claim 1, wherein anlotinib is in the form of a free base, or in the form of a pharmaceutically acceptable salt thereof.
